XEN 801

Drug Profile

XEN 801

Alternative Names: XEN801

Latest Information Update: 10 Jan 2017

Price : $50

At a glance

  • Originator Xenon Pharmaceuticals
  • Class Antiacnes; Small molecules
  • Mechanism of Action Stearoyl CoA desaturase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acne vulgaris
  • Preclinical Skin disorders

Most Recent Events

  • 04 Nov 2016 Xenon Pharmaceuticals completes enrolment in its phase I/II trial for Acne Vulgaris in Canada (NCT02656043)
  • 10 Feb 2016 Phase-II clinical trials in Acne vulgaris in Canada (Topical)
  • 10 Feb 2016 Adverse events data from a phase I part of phase II trial in Acne vulgaris released by Xenon Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top